Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants
PHASE1CompletedINTERVENTIONAL
Enrollment
44
Participants
Timeline
Start Date
February 16, 2024
Primary Completion Date
June 12, 2025
Study Completion Date
June 12, 2025
Conditions
Healthy Participants
Interventions
DRUG
mRNA-0184
Intravenous infusion
Trial Locations (1)
3004
Nucleus Network, Melbourne
All Listed Sponsors
lead
ModernaTX, Inc.
INDUSTRY
NCT06243770 - Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants | Biotech Hunter | Biotech Hunter